Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H9C1
UPID:
SPE39_HUMAN
Alternative names:
VPS33B-interacting protein in apical-basolateral polarity regulator; VPS33B-interacting protein in polarity and apical restriction
Alternative UPACC:
Q9H9C1; B4DPI6; O95434; Q9H7E1; Q9H9I9
Background:
Spermatogenesis-defective protein 39 homolog, also known as VPS33B-interacting protein, plays a crucial role in endosomal maturation, vesicular trafficking, and maintenance of apical-basolateral polarity. It is involved in the VPS33B:VIPAS39 complex, influencing epithelial cell recycling pathways and lysosomal trafficking, independent of VPS33B.
Therapeutic significance:
The protein's malfunction is linked to Arthrogryposis, renal dysfunction, and cholestasis syndrome 2, a multisystem disorder. Understanding its role could lead to novel therapeutic strategies for this and potentially other related diseases.